Abstract:Background While China has implemented reimbursement-linked drug price negotiation annually since 2017, emphasizing value-based pricing to achieve a value-based strategic purchase of medical insurance, whether drug prices became better aligned with clinical value after price negotiation has not been sufficiently established. This study aimed to assess the changes in prices and their relationship with the clinical value of anticancer drugs after the implementation of price negotiations in China. Methods and findings In this observational study, anticancer drug indications that were negotiated successfully between 2017 and 2022 were identified through National Reimbursement Drug Lists (NRDL) of China. We excluded extensions of indications for drugs already listed in the NRDL, indications for pediatric use, and indications lacking corresponding clinical trials. We identified pivotal clinical trials for included indications by consulting review reports or drug labels issued by the Center for Drug Evaluation, National Medical Products Administration. We calculated treatment costs as outcome measures based on publicly available prices and collected data on clinical value including safety, survival, quality of life, and overall response rate (ORR) from publications of pivotal clinical trials. The associations between drug costs and clinical value, both before and after negotiation, were analyzed using regression analyses. We also examined whether price negotiation has led to a reduction in the variation of treatment costs for a given value. We included 103 anticancer drug indications, primarily for the treatment of blood cancer, lung cancer, and breast cancer, with 76 supported by randomized controlled trials and 27 supported by single-arm clinical trials. The median treatment costs over the entire sample have been reduced from US$34,460.72 (interquartile range (IQR): 19,990.49 to 55,441.66) to US$13,688.79 (IQR: 7,746.97 to 21,750.97) after price negotiation ( P < 0.001). Before price negotiation, each additional month of survival gained was associated with an increase in treatment costs of 3.4% (95% confidence interval (CI) [2.1, 4.8], P < 0.001) for indications supported by randomized controlled trials, and a 10% increase in ORR was associated with a 6.0% (95% CI [1.6, 10.3], P = 0.009) increase in treatment costs for indications supported by single-arm clinical trials. After price negotiation, the associations between costs and clinical value may not have changed significantly, but the variation of drug costs for a given value was reduced. Study limitations include the lack of transparency in official data, missing data on clinical value, and a limited sample size. Conclusions In this study, we found that the implementation of price negotiation in China has led to drug pricing better aligned with clinical value for anticancer drugs even after substantial price reductions. The achievements made in China could shed light on the price regulation in other countries, particularly those with limited resources and increasing drug expenditures.

Were Economic Evaluations Well Reported for the Newly Listed Oncology Drugs in China’s National Reimbursement Drug List

Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review

PD08 A Systematic Review of Reporting Quality of Economic Evaluations in TCM in NRDL of China Based on CHEERS

Quality of Pharmacoeconomic Research in China

A systematic review on reporting quality of economic evaluations for negotiated glucose-lowering drugs in China national reimbursement drug list

OP46 Assessing The Quality Of Pharmacoeconomic Evaluations About Type 2 Diabetes Mellitus Drugs In National Reimbursement Drug List

PD12 Quality Assessment of Health Economic Evaluation on Screening Programs from China

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

System analysis and evaluation of pharmacoeconomic literatures of cancer published in China

The Quality of Published Health Economic Evaluations on Screening Programs in China: a Systematic Review and Quantitative Appraisal

Assessment of the quality of pharmacoeconomic evaluation literature in China

Price negotiation and pricing of anticancer drugs in China: An observational study

Does price negotiation in China bring high-value novel drugs to the national medical insurance beneficiaries?

Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005-2020: an observational study

Reporting Quality in Health Economic Evaluation Studies of Immune Checkpoint Inhibitors: A Systematic Review

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China

Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005–2020: an observational studyResearch in context

Differences in reimbursement listing of anticancer therapies in China: an observational study

Impact of competition on reimbursement decisions for cancer drugs in China: an observational study

A Critical Review of Chinese Pharmacoeconomics Studies in the Last Five Years.